Study examines best sequence of treatments for advanced bowel cancer

NCT ID NCT06137170

Completed Knowledge-focused Sponsor: Bayer Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at data from 121 people with metastatic colorectal cancer who received two approved treatments—regorafenib and TAS (with or without bevacizumab)—in different orders. Researchers want to see which sequence works better and how long patients live. Since this is an observational study using existing health records, no new treatments or visits are involved.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: regorafenib, TAS (trifluridine/tipiracil), bevacizumab
What this could lead to: If successful, this study could help doctors choose the best order of treatments for people with advanced colorectal cancer, potentially improving survival.
What could go wrong: This is an observational study using existing data, so it cannot prove cause and effect. Results may not apply to all patients or settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC COLORECTAL CANCER

Contacts and locations

Locations

Many Locations

Multiple Locations, France
Many Locations

Multiple Locations, Italy
Many Locations

Multiple Locations, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.